To further exclude a function of REV1 in tolerating cisplatin-induced lesions in human cells, we performed synergy experiments using multiple doses of cisplatin and REV1i in the p53-KO murine lymphoma, human MCF-7 and HCT116, human prostate cancer cell lines 22RV1 and LNCaP, human ovarian cancer cell SKOV3, MEFs, and human melanoma cell line A375 (see Supplementary table 3A for the concentrations). The gene discussed is TP53; the disease is lymphoma.